JP2017524685A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524685A5
JP2017524685A5 JP2016576082A JP2016576082A JP2017524685A5 JP 2017524685 A5 JP2017524685 A5 JP 2017524685A5 JP 2016576082 A JP2016576082 A JP 2016576082A JP 2016576082 A JP2016576082 A JP 2016576082A JP 2017524685 A5 JP2017524685 A5 JP 2017524685A5
Authority
JP
Japan
Prior art keywords
active agent
additive
layer
use according
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016576082A
Other languages
English (en)
Japanese (ja)
Other versions
JP6895755B2 (ja
JP2017524685A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/061109 external-priority patent/WO2015177209A1/en
Publication of JP2017524685A publication Critical patent/JP2017524685A/ja
Publication of JP2017524685A5 publication Critical patent/JP2017524685A5/ja
Application granted granted Critical
Publication of JP6895755B2 publication Critical patent/JP6895755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016576082A 2014-05-20 2015-05-20 経皮送達システムにおける活性薬剤の放出を調節するための方法 Active JP6895755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169026.3 2014-05-20
EP14169026 2014-05-20
PCT/EP2015/061109 WO2015177209A1 (en) 2014-05-20 2015-05-20 Method for adjusting the release of active agent in a transdermal delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019210979A Division JP2020055822A (ja) 2014-05-20 2019-11-22 経皮送達システムにおける活性薬剤の放出を調節するための方法

Publications (3)

Publication Number Publication Date
JP2017524685A JP2017524685A (ja) 2017-08-31
JP2017524685A5 true JP2017524685A5 (enExample) 2018-06-21
JP6895755B2 JP6895755B2 (ja) 2021-06-30

Family

ID=50735939

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016576082A Active JP6895755B2 (ja) 2014-05-20 2015-05-20 経皮送達システムにおける活性薬剤の放出を調節するための方法
JP2019210979A Pending JP2020055822A (ja) 2014-05-20 2019-11-22 経皮送達システムにおける活性薬剤の放出を調節するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019210979A Pending JP2020055822A (ja) 2014-05-20 2019-11-22 経皮送達システムにおける活性薬剤の放出を調節するための方法

Country Status (6)

Country Link
US (2) US11426359B2 (enExample)
EP (1) EP3145503A1 (enExample)
JP (2) JP6895755B2 (enExample)
CN (1) CN106456567A (enExample)
CA (1) CA2948219C (enExample)
WO (1) WO2015177209A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
TWI687239B (zh) * 2015-10-26 2020-03-11 日商久光製藥股份有限公司 貼附劑
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
JP7502199B2 (ja) * 2018-06-20 2024-06-18 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンを含有する経皮治療システム
WO2020102695A1 (en) 2018-11-16 2020-05-22 Cti (Assignment For Benefit Of Creditors) Llc Thermally regulated transdermal drug delivery system
ES2966170T3 (es) * 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4906463A (en) 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5300291A (en) 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5032207A (en) 1988-03-04 1991-07-16 Noven Pharmaceuticals, Inc. One-step method for forming a pressure-sensitive adhesive transdermal drug device
US4994278A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4814168A (en) 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5405486A (en) 1988-03-04 1995-04-11 Noven Pharmaceuticals, Inc. Apparatus for forming a transdermal drug device
DK0474647T3 (da) 1990-03-28 1997-08-18 Noven Pharma Fremgangsmåde og indretning til frigivelse af lægemidler til huden
AU2004092A (en) 1991-04-25 1992-12-21 Noven Pharmaceuticals, Inc. Method and apparatus for forming a transdermal drug device
US5387189A (en) 1993-12-02 1995-02-07 Alza Corporation Electrotransport delivery device and method of making same
US6449319B1 (en) 1998-03-20 2002-09-10 Koninklijke Philips Electronics N.V. Receiver with a clock signal generator
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6757560B1 (en) 1999-04-09 2004-06-29 Novosis Pharma Ag Transdermal delivery system (TDS) with electrode network
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6317630B1 (en) 1999-01-29 2001-11-13 Yossi Gross Drug delivery device
ES2260021T3 (es) 1999-06-08 2006-11-01 Altea Therapeutics Corporation Aparatos para la microporacion de membranas biologicas utilizando dispositivos de interfaz de tejido de pelicula delgada, y su metodo.
BR0012152A (pt) 1999-07-02 2002-03-12 Lohmann Therapie Syst Lts Sistema de microrreservatórios na base de polissiloxanos e solventes ambifìlicos
DE10012908B4 (de) 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
EP1381358B1 (en) 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
DE10118282A1 (de) 2001-04-12 2002-12-05 Lohmann Therapie Syst Lts Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
ATE251901T1 (de) 2001-05-08 2003-11-15 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
DK1256340T3 (da) 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
EP1453447A4 (en) 2001-08-17 2006-06-07 Lavipharm Lab Inc COMPOSITION AND DEVICE FOR TRANSDERMAL DRUG DELIVERY
DE10159745A1 (de) 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
US6775570B2 (en) 2002-02-04 2004-08-10 Ceramatec, Inc. Iontophoretic treatment device
US20030180281A1 (en) 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
EP1386605A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
EP1386604A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US7603144B2 (en) 2003-01-02 2009-10-13 Cymbet Corporation Active wireless tagging system on peel and stick substrate
CN100403477C (zh) 2003-01-02 2008-07-16 Cymbet公司 固态电池供电装置及其制造方法
BRPI0318250B8 (pt) 2003-04-14 2021-05-25 Lts Lohmann Therapie Systeme Ag emplastro tópico com matriz de polissiloxano e método para a produção de preparação de um emplastro tópico
JP2007522262A (ja) 2003-06-26 2007-08-09 シミックス・テクノロジーズ・インコーポレイテッド フォトレジストポリマー
WO2005009417A1 (en) 2003-07-21 2005-02-03 Noven Pharmaceuticals, Inc. Composition and method for controlling grug delivery from silicone adhesive blends
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361259A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US20050202073A1 (en) 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2005119610A1 (en) 2004-05-28 2005-12-15 Jan De Geest Communication unit for a person's skin
JP2006178807A (ja) 2004-12-24 2006-07-06 Echigo Fudagami Kk Ｉｃシート製造装置及びｉｃシート製造方法
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102006054733A1 (de) 2006-11-21 2008-05-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
JP2010536434A (ja) 2007-08-17 2010-12-02 イシス バイオポリマー エルエルシー イオン泳動薬物送達システム
EP2190430A1 (de) 2007-08-24 2010-06-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von von cycloheximid abgeleiteten verbindungen zur behandlung oder vorbeugung von insbesondere ischämien und herzerkrankungen
UY31406A1 (es) 2007-10-19 2009-05-29 "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
SI2215072T1 (sl) 2007-11-28 2015-10-30 Ucb Pharma Gmbh Polimorfna oblika rotigotina
AU2009262871B2 (en) 2008-05-30 2016-04-14 Mylan Inc. Stabilized transdermal drug delivery system
JP2009297808A (ja) 2008-06-11 2009-12-24 Chiyoda Integre Co Ltd 粘着テープ製造方法及び粘着テープ製造装置
EP2140861A1 (en) 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
AR074047A1 (es) 2008-09-09 2010-12-22 Transcu Ltd Sistemas, dispositivos, y metodos para suministrar energia a dispositivos, por ejemplo dispositivos de administracion transdermica y/o para controlarlos
EP2349230A2 (en) 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
WO2010129928A1 (en) 2009-05-08 2010-11-11 Isis Biopolymer Llc Iontophoretic device with improved counterelectrode
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
KR20160055971A (ko) * 2009-12-22 2016-05-18 유씨비 파르마 게엠베하 비결정질형 로티고틴의 고체 분산체의 안정화를 위한 폴리비닐피롤리돈
BR112013012117A8 (pt) 2010-11-23 2017-10-10 Nupathe Inc Sistema de distribuição de fármaco iontoforético coempacotado de utilização única coempacotado autocontido, usos de fármaco e de composto de triptano
WO2012084969A1 (en) * 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
EP2790685B1 (en) 2011-12-12 2017-08-16 LTS LOHMANN Therapie-Systeme AG Transdermal delivery system comprising buprenorphine
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
LT2810646T (lt) 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema

Similar Documents

Publication Publication Date Title
JP2017524685A5 (enExample)
JP7153010B2 (ja) 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法
JP2013526572A5 (enExample)
RU2015110825A (ru) Устойчивая к действию желудочного сока фармацевтическая или нутрицевтическая композиция со стойкостью к влиянию этанола
RU2014101227A (ru) Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм
JP2011529854A5 (enExample)
DK201600113U1 (da) Transdermalt, terapeutisk system til administration af rivastigmin
HRP20201880T1 (hr) Transdermalni terapijski sustav namijenjen primjeni aktivne tvari
JP2005528413A5 (enExample)
JP2014506914A5 (enExample)
JP2017515872A5 (enExample)
JP5514815B2 (ja) 経皮吸収製剤
EP3160461A1 (en) Transdermal delivery system
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
ES2829807T3 (es) Sistema de administración transdérmica de fármacos que contiene donepezilo
US9539201B2 (en) Selegiline transdermal system
CN106794155A (zh) 贴附剂
JP2018537451A5 (enExample)
JP2007284378A (ja) 選択的セロトニン再取込阻害成分を含有する製剤
JP6002055B2 (ja) 貼付剤
EP3302422A1 (en) Formulations for aripiprazole delivery transdermally
RU2015129081A (ru) Гелевые композиции
JP2021102573A (ja) クエン酸フェンタニル含有経皮吸収製剤
TH101950B (th) สูตรผสมทางยาสำหรับให้ทางผิวหนัง
Parati et al. OLMESARTAN MEDOXOMIL/AMLODIPINE (OLM/AML) IMPROVES BLOOD PRESSURE (BP) CONTROL THROUGHOUT 24 HOURS COMPARED WITH AML MONOTHERAPY IN PATIENTS WITH MODERATE-TO-SEVERE HYPERTENSION: PP. 5.210